Close
  Indian J Med Microbiol
 

Figure 6: Distribution of Tc99 m-radiolabeled certolizumab pegol (a tumor necrosis factor-α antibody) in sacroiliac joints 4–5 h postinjection in a patient with axial spondyloarthritis. Distinct bone marrow edema on magnetic resonance imaging (a) is shown in the right sacroiliac joint, with an increased tracer uptake on single-photon emission computed tomography (b). (c) is a fusion of magnetic resonance imaging and single-photon emission computed tomography

Figure 6: Distribution of Tc<sup>99</sup> <sup>m</sup>-radiolabeled certolizumab pegol (a tumor necrosis factor-α antibody) in sacroiliac joints 4–5 h postinjection in a patient with axial spondyloarthritis. Distinct bone marrow edema on magnetic resonance imaging (a) is shown in the right sacroiliac joint, with an increased tracer uptake on single-photon emission computed tomography (b). (c) is a fusion of magnetic resonance imaging and single-photon emission computed tomography